Twist Bioscience earnings beat by $0.06, revenue topped estimates
Twist Bioscience (TWST) reported Q4 EPS of -$0.32, beating estimates by $0.06, with revenue at $126.6M, exceeding expectations. The company forecasted Q1 2027 revenue of $130M-$132M and FY 2027 revenue of $550M-$560M, both above consensus. TWST's stock is up 3.39% over 3 months and 310% over 12 months.
How this was made
The 30-second read
Why it matters
Earnings beat and guidance raise expectations for revenue growth, likely supporting the stock in the short term.
Market read
The earnings surprise provides a fresh catalyst for traders, especially those tracking biotech and synthetic biology stocks.
What to watch
Potential supply‑chain constraints or upcoming regulatory reviews could temper upside.
Background
Twist Bioscience is a synthetic DNA manufacturer listed on NASDAQ. The company posted Q4 results that beat consensus and raised its FY 2027 revenue outlook.
Ticker impact
Twist Bioscience reported Q4 EPS of -$0.32 beating estimates by $0.06 and revenue of $126.6M beating the $123.59M consensus, plus raised FY 2027 revenue guidance.
likely upward pressure as the market prices in the earnings beat and higher guidance
The beat and guidance lift expectations for near‑term revenue growth, prompting traders to consider buying or adding to positions.
Market effects
Biotech manufacturing sector may see modest uplift as Twist's results suggest demand for synthetic DNA services.
US biotech stocks could see short‑term gains in response to the earnings beat.
Limited to investors focused on US‑listed biotech and synthetic biology firms.
Counterpoint
If the beat is already priced in, the stock may face short‑term profit taking.
Key entities
- companyTwist Bioscience
Synthetic DNA manufacturer reporting earnings.
